Exelixis submits cabozantinib NDA to FDA
Cabozantinib is a potent targeted therapy that inhibits MET, VEGFR2 and RET. As a part of the NDA filing, which is based on data from a Phase III
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.